A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions

Journal of Immunological Methods

Volumn 237, Issue 1-2, 2000, Pages 131-145

  Helfrich, Wijnand ^a   Haisma, Hidde J ^b   Magdolen, Victor ^c   Luther, Thomas ^d   Bom, Victor J J ^a   Westra, Jantine ^a   Van Der Hoeven, Renske ^a   Kroesen, Bart Jan ^a   Molema, Grietje ^a   De Leij, Lou ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Angiogenesis; Angiostatin; Antibody engineering; Bispecific; Carcinoma; Cytosine deaminase; Expression plasmid; Fusion protein; Prodrug enzyme; Targeting; Tissue factor

Indexed keywords

ANGIOSTATIN; BISPECIFIC ANTIBODY; CYTOSINE DEAMINASE; FC RECEPTOR; HYBRID PROTEIN; THROMBOPLASTIN;

ANGIOGENESIS; ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY PRODUCTION; ARTICLE; CELL LYSATE; CYTOTOXICITY; EXPRESSION VECTOR; GENETIC TRANSFECTION; MELANOMA CELL; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL;

ANGIOSTATINS; ANIMALS; BASE SEQUENCE; COS CELLS; CYTOSINE DEAMINASE; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MOLECULAR SEQUENCE DATA; NUCLEOSIDE DEAMINASES; PEPTIDE FRAGMENTS; PLASMIDS; PLASMINOGEN; PROTEIN FOLDING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; THROMBOPLASTIN; TRANSFECTION; TUMOR CELLS, CULTURED;

EUKARYOTA;

EID: 0034599932     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00220-3     Document Type: Article

References (36)

1. 2+, phospholipids and tissue factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem. J. 265:1990;327.
2. Clackson T., Hoogenboom H.R., Griffiths A.D., Winter G. Making antibody fragments using phage display libraries. Nature. 352:1991;624.
3. De Jonge J., Brissinck J., Heirman C., Demanet C., Leo O., Moser M., Thielemans K. Production and characterization of bispecific single-chain antibody fragments. Mol. Immunol. 32:1995;1405.
4. De Leij L., Helfrich W., Stein R., Mattes M.J. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int. J. Cancer. 57:(Suppl. 8):1994;60.
5. Deonarain M.P., Epenetos A.A. Targeting enzymes for cancer therapy: old enzymes in new roles. Br. J. Cancer. 70:1994;786.
6. Evan G.I., Lewis G.K., Ramsay G., Bishop J.M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell Biol. 5:1985;3610.
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature. 1:1995;27.
8. Garcia Sanchez F., Pizzorno G., Fu S.Q., Nanakorn T., Krause D.S., Liang J., Adams E., Leffert J.J., Yin L.H., Cooperberg M.R., Hanania E., Wang W.L., Won J.H., Peng X.Y., Cote R., Brown R., Burtness B., Giles R., Crystal R., Deisseroth A.B. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood. 92:1998;672.
9. Haack K., Moebius U., Knebel Doeberitz M.V., Herfarth C., Schackert H.K., Gebert J.F. Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Hum. Gene Ther. 8:1997;1395.
10. Helfrich W., Van Geel M., The T.H., De Leij L. Detection of a putative 30-kDa ligand of the cluster-2 antigen. Int. J. Cancer. 57:(Suppl. 8):1994;70.
11. Helfrich W., Kroesen B.J., Roovers R.C., Westers L., Molema G., Hoogenboom H.R., De Leij L. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int. J. Cancer. 76:1998;232.
12. Holliger P., Prospero T., Winter G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA. 90:1993;6444.
13. Holliger P., Brissinck J., Williams R.L., Thielemans K., Winter G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. 9:1996;299.
14. Holliger P., Wing M., Pound J.D., Bohlen H., Winter G. Retargeting serum immunoglobulin with bispecific diabodies. Nat. Biotechnol. 15:1997;632.
15. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547.
16. Janson T.L., Stormorken H., Prydz H. Species specificity of tissue thromboplastin. Haemostasis. 14:1984;440.
17. Jost C.R., Titus J.A., Kurucz I., Segal D.M. A single-chain bispecific Fv-2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol. Immunol. 33:1996;211.
18. Kievit E., Bershad E., Ng E., Sethna P., Dev I., Lawrence T.S., Rehemtulla A. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 59:1999;1417.
19. Kilstrup M., Meng L.M., Neuhard J., Nygaard P. Genetic evidence for a repressor of synthesis of cytosine deaminase and purine biosynthesis enzymes in Escherichia coli. J. Bacteriol. 171:1989;2124.
20. Kostelny S.A., Cole M.S., Tso J.Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148:1992;1547.
21. Mack M., Gruber R., Schmidt S., Riethmuller G., Kufer P. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J. Immunol. 158:1997;3965.
22. Magdolen V., Albrecht S., Kotzsch M., Haller C., Burgle M., Jacob U., Grosser M., Kessler H., Graeff H., Muller M., Schmitt M., Luther T. Immunological and functional analyses of the extracellular domain of human tissue factor. Biol. Chem. 379:1998;157.
23. Molema G., de Leij L.F.M.H., Meijer D.K. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res. 14:1997;2.
24. Molema G., Meijer D.K., de Leij L.F.M.H. Tumor vasculature targeted therapies: getting the players organized. Biochem. Pharmacol. 55:1998;1939.
25. Molema G., Schraa A.J., Moorlag H., de Leij L.F.M.H., Meijer D.K.F. Development of angiostatin derivates for targeting therapeutics to tumor vasculature: LBS-1 pharmacokinetics. Proc. AACR. 40:1999;419.
26. Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P., Everitt L., Hubchak S., Schnaper H.W., Pizzo S.V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA. 92:1999;2811.
27. Mullen C.A., Kilstrup M., Blaese R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA. 89:1992;33.
28. Nissim A., Hoogenboom H.R., Tomlinson I.M., Flynn G., Midgley C., Lane D.W. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13:1994;692.
29. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315.
30. Rodrigues M.L., Shalaby M.R., Werther W., Presta L., Carter P. Engineering a humanized bispecific F(ab′)2 fragment for improved binding to T cells. Int. J. Cancer. 7:(Suppl.):1992;45.
31. Roovers R.C., Henderikx P., Helfrich W., van der Linden E., Reurs A., de Bruine A.P., Arends J.W., de Leij L., Hoogenboom H.R. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br. J. Cancer. 78:1998;1407.
32. Rosendahl A., Hansson J., Sundstedt A., Kalland T., Dohlsten M. Immune response during tumor therapy with antibody-superantigen fusion proteins. Int. J. Cancer. 68:1996;109.
33. Sim B.K., O'Reilly M.S., Liang H., Fortier A.H., He W., Madsen J.W., Lapcevich R., Nacy C.A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57:1997;1329.
34. Szala S., Froehlich M., Scollon M., Kasai Y., Steplewski Z., Koprowski H., Linnenbach A.J. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc. Natl. Acad. Sci. USA. 87:1990;3542.
35. Viti F., Tarli L., Giovannoni L., Zardi L., Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59:1999;347.
36. Wallace P.M., MacMaster J.F., Smith V.F., Kerr D.E., Senter P.D., Cosand W.L. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5- fluorocytosine. Cancer Res. 54:1994;2719.